Skip to main content
SpringerLink
Log in

Advances in the Management of Paget’s Disease of Bone

  • Practical Therapeutics
  • Published:
Drugs Aims and scope Submit manuscript

Summary

The advent of potent new bisphosphonates (diphosphonates) now makes it possible to restore and maintain normal bone turnover in many patients with Paget’s disease of bone (osteitis deformans). This has necessitated a reappraisal of the indications for treatment, the ways in which disease activity and response are assessed, as well as the place of existing therapies

Measurements of urinary hydroxyproline and serum alkaline phosphatase remain the most useful markers of disease activity. Pyridinium crosslinks may prove to be more specifibrillationc than hydroxyproline in the assessment of bone resorption but osteocalcin has been disappointing in monitoring the effect of treatment on bone formation

Etidronic acid (disodium etidronate), the first bisphosphonate introduced for clinical use, is a potent inhibitor of osteoclastic bone resorption but its potential is limited by the development of defective mineralisation with high dosage (10 to 20 mg/kg/day). The newer bisphosphonates, clodronic acid (clodronate) and pamidronic acid (pamidronate, APD), are free from this problem and appear able to control a wide range of disease activity. A small number of patients appear resistant to the agents but the underlying mechanism is unclear. The effibrillationcacy and safety of these bisphosphonates makes it likely that the threshold for treating asymptomatic patients will fall in the hope of preventing long term complications

These developments will lead to a reappraisal of the role of calcitonin which can now be administered by both the parenteral and intranasal routes. One focus of interest will be on the quality of the bone laid down during treatment. Meticulous radiographic studies have shown that calcitonin improves bone architecture and this may have particular relevance to the treatment of lytic disease. The relative merits of the different forms of therapy for Paget’s disease need further evaluation, particularly with respect to the identifibrillationcation of specifibrillationc advantages of individual drugs

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Adami S, Guarrera G, Salvagno G, Spiazzi G, Marini G, et al. Sequential treatment of Paget’s disease with human calcitonin and dichloromethylene diphosphonate (CL2MDP). Metabolic Bone Disease and Related Research 5: 265–267, 1984

    Article  CAS  Google Scholar 

  • Adami S, Salvagno G, Guarrera G, Montesanti F, Garavelli S, et al. Treatment of Paget’s disease of bone with intravenous 4 amino-l-hydroxybutylidene-1, 1-bisphosphonate. Calcified Tissue International 39: 226–229, 1986

    Article  PubMed  CAS  Google Scholar 

  • Altman RD. Long term follow up of therapy with intermittent etidronate disodium in Paget’s disease of bone. American Journal of Medicine 79: 583–590, 1985

    Article  PubMed  CAS  Google Scholar 

  • Altman RD, Collins-Yudiskas B. Synthetic human calcitonin in refractory Paget’s disease of bone. Archives of Internal Medicine 147: 1305–1308, 1987

    Article  PubMed  CAS  Google Scholar 

  • Atkins RM, Yates AJP, Gray RES, Urwin GH, Hamdy NAT, et al. Aminohexane diphosphonate in the treatment of Paget’s disease of bone. Journal of Bone and Mineral Research 2: 273–279, 1987

    Article  PubMed  CAS  Google Scholar 

  • Audran M, Clochon P, Etghen D, Mazieres B, Renier JC. Treatment of Paget’s disease of bone with (4-chloro-phenyl) thiomethyline bisphosphonate. Clinical Rheumatology 8: 71–79, 1989

    Article  PubMed  CAS  Google Scholar 

  • Avioli LV. Paget’s disease: state of the art. Clinical Therapeutics 9: 567–576, 1987

    PubMed  CAS  Google Scholar 

  • Avramides A, Flores A, De Rose J, Wallach S. Paget’s disease of bone: observations after cessation of long term synthetic salmon calcitonin treatment. Journal of Clinical Endocrinology and Metabolism 42: 459–463, 1976

    Article  PubMed  CAS  Google Scholar 

  • Bijvoet OLM, Hosking DJ, Frijlink WB, TeVelde J, Vellenga CJLR. Treatment of Paget’s disease with combined calcitonin and diphosphonate (EHDP). Metabolic Bone Disease and Related Research 1: 251–256, 1978

    Article  Google Scholar 

  • Black D, Duncan A, Robins SP. Quantitative analyses of the pyridinium crosslinks of collagen in urine using iron-paired reversed-phase high-performance liquid chromatography. Analytical Biochemistry 169: 197–203, 1988

    Article  PubMed  CAS  Google Scholar 

  • Black D, Farquharson C, Robins SP. Excretion of pyridinium cross links of collagen in ovariectomised rats as urinary markers for increased bone resorption. Calcifibrillationed Tissue International 44: 343–347, 1989

    Article  CAS  Google Scholar 

  • Boonekamp PN, v.d. Wee-Pals LJA, v Wijk-v, Lennep MML, Thesingh CW, Bijvoet OLM. Two modes of action of bisphosphonates on osteoclastic resorption of mineralised matrix. Bone and Mineral 1: 27–39, 1986

    PubMed  CAS  Google Scholar 

  • Bounameaux HM, Schifferli J, Montani J-P, Jung A, Chatelanat F. Renal failure associated with intravenous diphosphonates. Lancet 1: 471, 1983

    Article  PubMed  CAS  Google Scholar 

  • Bouvet JP. Traitement de la maladie de Paget par la thyrocalcitonine de saumon: étude cooperative en double insu. Nouvelle Presse Medicale 6: 1447–1450, 1977

    Google Scholar 

  • Buclin T, Randin JP, Jacquet AF, Azria M, Attinger M, et al. The effect of rectal and nasal administration of salmon calcitonin in normal subjects. Calcifibrillationed Tissue International 41: 252–258, 1987

    Article  CAS  Google Scholar 

  • Cantrill JA, Buckler HM, Anderson DC. Low dose intravenous 3-amino-l-hydroxypropylidine-l, 1-bisphosphonate (APD) for the treatment of Paget’s disease of bone. Annals of the Rheumatic Diseases 45: 1012–1018, 1986

    Article  PubMed  CAS  Google Scholar 

  • Chapuy MC, Charhon SA, Meunier PJ. Sustained biochemical effects of short treatment of Paget’s disease of bone with dichloromethylene diphosphonate. Metabolic Bone Disease and Related Research 4: 325–328, 1983

    CAS  Google Scholar 

  • Collins DH. Paget’s disease of bone: incidence and subclinical forms. Lancet 2: 51–57, 1956

    Article  Google Scholar 

  • Coulton LA, Preston CJ, Cough M, Kanis JA. An evaluation of serum osteocalcin in Paget’s disease of bone and its response to diphosphonate treatment. Arthritis and Rheumatism 31: 1142–1147, 1988

    Article  PubMed  CAS  Google Scholar 

  • D’Agostino HR, Barnett CA, Zielinski XJ, Gordan GS. Intranasal salmon calcitonin treatment of Paget’s disease of bone. Clinical Orthopaedics and Related Research 230: 223–228, 1988

    PubMed  Google Scholar 

  • Delmas PD, Chapuy M-C, Edouard C, Meunier PJ. Beneficial effects of aminohexane diphosphonate in patients with Paget’s disease of bone resistant to sodium etidronate. American Journal of Medicine 83: 276–282, 1987

    Article  PubMed  CAS  Google Scholar 

  • Delmas PD, Chapuy MC, Vignon E, Charon S, Briancon D, et al. Long term effects of dichloromethylene diphosphonate in Paget’s disease of bone. Journal of Clinical Endocrinology and Metabolism 54: 837–844, 1982

    Article  PubMed  CAS  Google Scholar 

  • Dodd GW, Ibbertson HK, Fraser TRC, Holdaway IM, Wattie D. Radiological assessment of Paget’s disease of bone after treatment with the bisphosphonates EHDP and APD. British Journal of Radiology 60: 849–860, 1987

    Article  PubMed  CAS  Google Scholar 

  • Douglas DL, Duckworth T, Kanis JA, Preston D, Beard DJ, et al. Biochemical and clinical responses to dichloromethylene diphosphonate (C12MDP) in Paget’s disease of bone. Arthritis and Rheumatism 23: 1185–1192, 1980

    Article  PubMed  CAS  Google Scholar 

  • Douglas DL, Kanis JA, Duckworth T, Beard DJ, Paterson AD, et al. Paget’s disease. Improvement of spinal cord dysfunction with diphosphonates and calcitonin. Metabolic Bone Disease and Related Research 3: 327–335, 1981

    Article  CAS  Google Scholar 

  • El Sammaa M, Linthicum FH, House HP, House JW. Calcitonin as treatment for hearing loss in Paget’s disease. American Journal of Otology 7: 241–243, 1986

    PubMed  Google Scholar 

  • Fleisch H. Experimental basis for the use of bisphosphonates in Paget’s disease of bone. Clinical Orthopaedics and Related Research 217: 72–78, 1987

    PubMed  Google Scholar 

  • Foldes J, Shamir S, Kidroni G, Menczel J. Vitamin D in Paget’s disease of bone. Clinical Orthopaedics and Related Research 243: 275–279, 1989

    PubMed  Google Scholar 

  • Frijlink WB, Bijvoet OLM, TeVelde J, Heynen G. Treatment of Paget’s disease with (3-amino-l-hydroxypropylidene)-l, 1-biphosphonate (APD). Lancet 1: 799–803, 1979

    Article  PubMed  CAS  Google Scholar 

  • Gagel RF, Logan C, Mallette LE. Treatment of Paget’s disease of bone with salmon calcitonin nasal spray. Journal of the American Geriatric Society 36: 1011–1014, 1988

    Google Scholar 

  • Gonzalez D, Vega E, Ghiringhelli G, Mautalen C. Comparison of the acute effect of the intranasal and intramuscular administration of salmon calcitonin in Paget’s disease. Calcified Tissue International 41: 313–315, 1987

    Article  PubMed  CAS  Google Scholar 

  • Gray RES, Yates AJP, Preston CJ, Smith R, Russell RGG. Duration of effect of oral diphosphonate therapy in Paget’s disease of bone. Quarterly Journal of Medicine 64: 755–767, 1987

    PubMed  CAS  Google Scholar 

  • Gruszkiewicz J, Doron Y, Borovich B, Zaaroor M. Spinal cord compression in Paget’s disease of bone with reference to sarcomatous degeneration and calcitonin treatment. Surgical Neurology 27: 117–125, 1987

    Article  PubMed  CAS  Google Scholar 

  • Hadjipavlou AG, Tsoukas GM, Siller TN, Danais S, Greenwood F. Combined drug therapy in treatment of Paget’s disease of bone. Journal of Bone and Joint Surgery 59A: 1045–1051, 1977

    Google Scholar 

  • Hamdy RC. Paget’s disease of bone, pp. 1–3, Praeger Scientifibrillationc, New York, 1981

    Google Scholar 

  • Harinck HIJ, Bijvoet OLM, Blanksma HJ, Dahlinghaus-Nienhuys PJ. Efficacious management with aminobisphosphonate (APD) in Paget’s disease of bone. Clinical Orthopaedics and Related Research 217: 79–98, 1987a

    PubMed  Google Scholar 

  • Harinck HIJ, Papapoulos SE, Blanksma HJ, Moolenaar AJ, Vermeij P, et al. Paget’s disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidine bisphosphonate (APD). British Medical Journal 295: 1301–1305, 1987b

    Article  PubMed  CAS  Google Scholar 

  • Hosking DJ. Paget’s disease of bone: an update on management. Drugs 30: 156–173, 1985

    Article  PubMed  CAS  Google Scholar 

  • Hosking DJ, Bijvoet OLM, Van Aken J, Will EJ. Paget’s disease of bone treated with diphosphonate and calcitonin. Lancet 1: 615–616, 1976

    Article  PubMed  CAS  Google Scholar 

  • Ibbertson HK, Henley JW, Fraser TR, Tait B, Stevens EJ, et al. Paget’s disease of bone: clinical evaluation and treatment with bisphosphonate. Australian and New Zealand Journal of Medicine 9: 31–35, 1979

    Article  PubMed  CAS  Google Scholar 

  • Kanis JSA, Gray RES. Long term follow up observations on treatment in Paget’s disease of bone. Clinical Orthopaedics and Related Research 217: 99–125, 1987

    PubMed  Google Scholar 

  • Kurose H, Seino Y, Shima M, Tanaka H, Ishida M, et al. Intranasal absorption of salmon calcitonin. Calcifibrillationed Tissue International 41: 249–251, 1987

    Article  CAS  Google Scholar 

  • Lando M, Hoover LA, Finerman G. Stabilisation of hearing loss in Paget’s disease with calcitonin and etidronate. Archives of Otolaryngology, Head and Neck Surgery 114: 891–894, 1988

    Article  CAS  Google Scholar 

  • Levy F, Muff R, Dotti-Sigrist S, Dambacher MA, Fischer JA. Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of Paget’s disease. Journal of Clinical Endocrinology and Metabolism 67: 541–545, 1988

    Article  PubMed  CAS  Google Scholar 

  • Lian JB, Friedman PA. The vitamin K-dependent synthesis of carboxyglutamic acid by bone microsomes. Journal of Biological Chemistry 253: 6623–6626, 1978

    PubMed  CAS  Google Scholar 

  • Maclntyre I, Alevizaki M, Bevis PJR, Zaidi M. Calcitonin and the peptides from the calcitonin gene. Clinical Orthopaedics and Related Research 217: 45–55, 1987

    Google Scholar 

  • McDonald DJ, Sim FH. Total hip arthropathy in Paget’s disease. Journal of Bone and Joint Surgery 69A: 766–772, 1987

    Google Scholar 

  • Meunier PJ, Chapuy MC, Alexandre C, Bressot C, Edouard C, et al. Effects of disodium dichloromethylene diphosphonate on Paget’s disease of bone. Lancet 2: 489–492, 1979

    Article  PubMed  CAS  Google Scholar 

  • Nagant De Deuxchaisnes C, Devogelaer JP, Huaux JP, Dufour JP, Esselinckx W, et al. New modes of administration of salmon calcitonin in Paget’s disease. Clinical Orthopaedics and Related Research 217: 56–71, 1987

    Google Scholar 

  • Nagant De Deuxchaisnes C, Rombouts-Lindemans C, Huaux JP, Devogelaer JP, Malghem J, et al. Roentenologic evaluation of the action of the diphosphonate EHDP and of combined therapy (EHDP and calcitonin) in Paget’s disease of bone. In Maclntyre & Szelke (Eds) Molecular endocrinology, pp. 405–433, Elsevier/North Holland Biomedical Press, Amsterdam, 1979

    Google Scholar 

  • Nagant De Deuxchaisnes C, Rombouts-Lindemans C, Huaux JP, Devogelaer JP, Malghem J, et al. Calcitonin or diphosphonates for osteolytic Paget’s disease. Lancet 1: 374, 1980

    Article  Google Scholar 

  • Nagant De Deuxchaisnes C, Rombouts-Lindemans C, Huaux JP, Malghem J, Maldague B. Roentgenologic evaluation of the effibrillationcacy of calcitonin in Paget’s disease of bone. In Maclntyre & Szelke (Eds) Molecular endocrinology, pp. 213–233, Elsevier/ North Holland Biomedical Press, Amsterdam, 1977

    Google Scholar 

  • O’Doherty DP, Bickerstaff DR, McCloskey EV, Atkins R, Hamdy NAT, et al. A comparison of the acute effects of subcutaneous and intranasal calcitonin. Clinical Science 78: 215–219, 1990

    PubMed  Google Scholar 

  • O’Donoghue DJ, Hosking DJ. Biochemical response to combination of disodium etidronate with calcitonin in Paget’s disease. Bone 8: 219–225, 1987

    Article  PubMed  Google Scholar 

  • Ogawa T, Ono T, Tsuda M, Kawanishi Y. A novel fluor in insoluble collagen: a cross linking moiety in collagen molecule. Biochemical and Biophysical Research Communications 107: 1252–1257, 1982

    Article  PubMed  CAS  Google Scholar 

  • Papapoulos SE, Frolich M, Mudde AH, Harinck HIJ, v.d. Berg H, et a. Serum osteocalcin in Paget’s disease of bone: basal concentrations and response to bisphosphonate treatment. Journal of Clinical Endocrinology and Metabolism 65: 89–94, 1987

    Article  PubMed  CAS  Google Scholar 

  • Papapoulos SE, Harinck HIJ, Bijvoet OLM, Gleed JH, Fraher LJ, et al. Effects of decreasing serum calcium on circulating parathyroid hormone and vitamin metabolites in normocalcaemic and hypercalcaemic patients treated with APD. Bone and Mineral 1: 69–78, 1986

    PubMed  CAS  Google Scholar 

  • Perry HM, Droke DM, Avioli LV. Alternate calcitonin and etidronate disodium therapy for Paget’s bone disease. Archives of Internal Medicine 144: 929–933, 1984

    Article  PubMed  Google Scholar 

  • Porrini AA, Maldonado Cocco JA, Garcia Morteo O. Spinal artery steal syndrome in Paget’s disease of bone. Clinical and Experimental Rheumatology 5: 377–378, 1987

    PubMed  CAS  Google Scholar 

  • Preston CJ, Yates AJP, Beneton MNC, Russell RGG, Gray RES, et al. Effective short term treatment of Paget’s disease with oral etidronate. British Medical Journal 292: 79–80, 1986

    Article  PubMed  CAS  Google Scholar 

  • Ralston SH, Boyce BF, Cowan RA, Fogelman I, Smith ML, et al. The effect of 1-hydroxyvitamin D3 on the mineralisation defect in disodium etidronate treated Paget’s disease — a double blind randomised clinical study. Journal of Bone and Mineral Research 2: 5–12, 1987

    Article  PubMed  CAS  Google Scholar 

  • Redden JF, Dixon J, Vennart W, Hosking DJ. Management of fissure fractures in Paget’s disease. International Orthopaedics 5: 103–106, 1981

    Article  PubMed  CAS  Google Scholar 

  • Reginster JY, Denis D, Albert A, Franchimont P. Assessment of the biological effectiveness of nasal synthetic salmon calcitonin (SSCT) by comparison with intramuscular (IM) or placebo injection in normal subjects. Bone and Mineral 2: 133–140, 1987

    PubMed  CAS  Google Scholar 

  • Reginster JY, Jeugmans-Huynen AM, Albert A, Denis D, Deroisy R, et al. Biological and clinical assessment of a new bisphosphonate, (chloro-4-phenyl) thiomethylene bisphosphonate in the treatment of Paget’s disease of bone. Bone 9: 349–354, 1988a

    Article  PubMed  CAS  Google Scholar 

  • Reginster JY, Jeugmans-Huynen AM, Albert A, Denis D, Franchimont P. One year’s treatment of Paget’s disease of bone by synthetic salmon calcitonin as a nasal spray. Journal of Bone and Mineral Research 3: 249–252, 1988b

    Article  PubMed  CAS  Google Scholar 

  • Reitsma PH, Teitelbaum SL, Bijvoet OLM, Kahn AJ. Differential action of the bisphosphonate (3 amino-1-hydroxypropylidene)-1-1-bisphosphonate (APD) and disodium dichloromethylene bisphosphonate (Cl2MDP) on rat macrophage-mediated bone resorption in vitro. Journal of Clinical Investigation 70: 927–933, 1982

    Article  PubMed  CAS  Google Scholar 

  • Rico H, Hernandez ER, Younes M, Hernandez D, Espinos D. Biochemical assessment of acute and chronic treatment of Paget’s bone disease with calcitonin and calcium with and without bisphosphonate. Bone 9: 63–66, 1988

    Article  PubMed  CAS  Google Scholar 

  • Sadar ES, Walton RT, Gossman HH. Neurological dysfunction in Paget’s disease of the vertebral column. Journal of Neurosurgery 37: 661–665, 1972

    Article  PubMed  CAS  Google Scholar 

  • Singer FR, Mills BG. Paget’s disease of bone: etiologic and therapeutic aspects. In Peck WA (Ed.) Bone and mineral research annual 2, pp. 394–421, Elsevier Science, Amsterdam, 1983

    Google Scholar 

  • Siris ES, Clemens TP, McMahon D, Gordon A, Jacobs TP. Parathyroid function in Paget’s disease of bone. Journal of Bone and Mineral Research 4: 75–79, 1989

    Article  PubMed  CAS  Google Scholar 

  • Stumpf JL. Pharmacologic management of Paget’s disease. Clinical Pharmacy 8: 485–495, 1989

    PubMed  CAS  Google Scholar 

  • Thiebaud D, Jaeger P, Burckhardt P. Paget’s disease of bone treated in five days with AHPrBP (APD) per os. Journal of Bone and Mineral Research 2: 45–52, 1987

    Article  PubMed  CAS  Google Scholar 

  • Thiebaud D, Jaeger P, Gobelet C, Jacquet AF, Burckhardt P. A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget’s disease of bone. American Journal of Medicine 85: 207–212, 1988

    Article  PubMed  CAS  Google Scholar 

  • Vega E, Gonzalez D, Ghiringhelli G, Mautalen C. Intravenous aminopropylidene bisphosphonate (APD) in the treatment of Paget’s bone disease. Journal of Bone and Mineral Research 2: 267–271, 1987

    Article  PubMed  CAS  Google Scholar 

  • Yates AJP. Paget’s disease of bone. Clinics in Endocrinology and Metabolism 2: 267–284, 1988

    CAS  Google Scholar 

  • Yates AJP, Gray RES, Urwin GH, Preston CJ, Russell RGG, et al. Intravenous clodronate in the treatment and retreatment of Paget’s disease of bone. Lancet 1: 1474–1477, 1985

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. City Hospital, Hucknall Road, Nottingham, NG5 1PB, England

    D. J. Hosking (Consulting Physician)

Authors
  1. D. J. Hosking
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hosking, D.J. Advances in the Management of Paget’s Disease of Bone. Drugs 40, 829–840 (1990). https://doi.org/10.2165/00003495-199040060-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199040060-00005

Keywords

Search

Navigation